<p>SG Americas Securities LLC 在第二季度根據最新提交給證券交易委員會（SEC）的 13F 申報文件，將其在 Rhythm Pharmaceuticals, Inc.（NASDAQ: RYTM - 免費報告）的持股增加了 348.9%。該基金在該期間購買了額外的 26,214 股，持有公司股票 33,727 股。根據最新的 SEC 申報，SG Americas Securities LLC 持有的 Rhythm Pharmaceuticals 股份價值 1,385,000 美元，佔公司價值的 0.06%。</p>
<p>獲取 <strong>Rhythm Pharmaceuticals</strong> 警報：</p>
<ul>
<li>7 支將推動減肥藥市場的股票</li>
</ul>
<p>許多其他機構投資者和對沖基金最近也買入和賣出了該股。Perceptive Advisors LLC 在第四季度將其在 Rhythm Pharmaceuticals 的持倉增加了 465.6%。Perceptive Advisors LLC 現在擁有公司股票 2,154,110 股，價值 99,024,000 美元，比上一季度增加了 1,773,282 股。安大略醫療養老金信託基金在第一季度將其在 Rhythm Pharmaceuticals 的持股增加了 381.2%。安大略醫療養老金信託基金現在擁有公司股票 730,643 股，價值 31,659,000 美元，比上一季度增加了 578,800 股。加拿大養老金計劃投資委員會在第一季度將其在 Rhythm Pharmaceuticals 的持股增加了 116.1%。加拿大養老金計劃投資委員會現在擁有公司股票 577,000 股，價值 25,001,000 美元，比上一季度增加了 310,000 股。Artisan Partners Limited Partnership 在第四季度購入了 Rhythm Pharmaceuticals 的新股份，價值約 12,477,000 美元。最後，Vanguard Group Inc.在第四季度將其在 Rhythm Pharmaceuticals 的持股增加了 7.0%。Vanguard Group Inc.現在擁有公司股票 3,226,938 股，價值 148,342,000 美元，比上一季度增加了 212,370 股。</p>
<h2>Rhythm Pharmaceuticals 股價表現</h2>
<p>NASDAQ RYTM 週五開盤價為 46.70 美元。公司的 50 天簡單移動平均線為 44.81 美元，200 天簡單移動平均線為 42.84 美元。該公司的市值為 28.5 億美元，市盈率為-10.09，貝塔係數為 2.04。Rhythm Pharmaceuticals, Inc.的一年最低價為 20.97 美元，最高價為 53.92 美元。</p>
<ul>
<li>2 家有前景的減肥藥生物技術公司</li>
</ul>
<p>Rhythm Pharmaceuticals（NASDAQ: RYTM - 獲取免費報告）於 8 月 6 日星期二發佈了季度財報。公司報告該季度每股虧損（EPS）為（0.55）美元，超過了每股（EPS）為（0.71）美元的共識預期 0.16 美元。Rhythm Pharmaceuticals 的淨利潤率為-254.88%，淨資產收益率為-221.65%。該季度公司營收為 2908 萬美元，高於共識預期的 2879 萬美元。與去年同期相比，Rhythm Pharmaceuticals 的季度營收增長了 51.3%。平均而言，股票研究分析師預計 Rhythm Pharmaceuticals, Inc.在本財年將實現-4.4 美元的每股收益。</p>
<h2>Rhythm Pharmaceuticals 內部交易活動</h2>
<p>根據其他 Rhythm Pharmaceuticals 的消息，內部人員 Joseph Shulman 於 7 月 16 日星期二出售了 10,468 股公司股票。這些股票的平均價格為 53.00 美元，總交易額為 554,804.00 美元。交易完成後，該內部人員在公司持有 30 股，價值 1,590 美元。該交易已在 SEC 的法律文件中披露，可在 SEC 網站上找到。此外，內部人員 Joseph Shulman 於 7 月 16 日星期二又以每股 53.00 美元的平均價格出售了 10,468 股 Rhythm Pharmaceuticals 股票，總交易額為 554,804.00 美元。交易完成後，該內部人員在公司持有 30 股，價值 1,590 美元。該交易已在證券交易委員會的法律文件中披露，可在 SEC 網站上找到。此外，內部人員 Pamela J. Cramer 於 7 月 29 日星期一以每股 49.06 美元的平均價格出售了公司股票 1,395 股，總交易額為 68,438.70 美元。交易完成後，該內部人員在公司持有 31,735 股公司股票，價值 1,556,919.10 美元。過去三個月，內部人員共出售了價值 3,101,567 美元的 66182 股公司股票。公司內部人員持有公司股票的比例為 5.60%。</p>
<h2>華爾街分析師的觀點</h2>
<p>一些分析師對該股發表了評論。Needham &amp; Company LLC 在 8 月 7 日星期三的研究報告中重申了對 Rhythm Pharmaceuticals 股票的 “買入” 評級，並給出了 55.00 美元的目標價。富國銀行在 4 月 18 日星期四的研究報告中將 Rhythm Pharmaceuticals 的目標價從 53.00 美元降至 52.00 美元，並給予該公司 “超重” 評級。美國銀行將 Rhythm Pharmaceuticals 的評級從 “買入” 調降至 “中性”，並將股票的價格目標從 49.00 美元降至 42.00 美元。最後，Canaccord Genuity Group 將 Rhythm Pharmaceuticals 的目標股價從 80.00 美元降至 79.00 美元，並給予該公司 “買入” 評級。一位研究分析師對該股給予持有評級，五位分析師給予買入評級。根據 MarketBeat.com 的數據，該股目前的平均評級為 “中等買入”，共識目標股價為 55.83 美元。</p>
<p><strong>查看我們關於 RYTM 的最新研究報告</strong></p>
<h2>Rhythm Pharmaceuticals 公司簡介（免費報告）</h2>
<p>Rhythm Pharmaceuticals, Inc.是一家專注於罕見神經內分泌疾病的商業階段生物製藥公司。該公司的主力產品候選藥是 IMCIVREE（setmelanotide），用於治療 POMC、PCSK1、LEPR 缺陷性肥胖以及 Bardet-Biedl 綜合徵和 Alström 綜合徵。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們比 Rhythm Pharmaceuticals 更喜歡的股票</li>
<li>什麼是債券市場假日？如何投資和交易</li>
<li>邁克爾·伯裏的阿里巴巴賭注及更廣泛的市場影響</li>
<li>如何投資 FAANG 股票</li>
<li>傑夫·布朗的 Exegesis AI 股票推薦</li>
<li>對投資者最重要的沃倫·巴菲特股票：他自己的</li>
<li>沃倫·巴菲特的賭注：為什麼伯克希爾·哈撒韋購買了奧爾特股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p>
<p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 2024 年的科技恐慌：億萬富翁知道的你不知道的（來自 InvestorPlace）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5"/></p>
<h2>現在是否值得投資 1,000 美元購買 Rhythm Pharmaceuticals？</h2>
<p>在考慮 Rhythm Pharmaceuticals 之前，您需要聽到這個消息。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單...而 Rhythm Pharmaceuticals 並不在其中。</p>
<p>儘管 Rhythm Pharmaceuticals 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

RYTM

<p>SG Americas Securities LLC 在第二季度增持了 Rhythm Pharmaceuticals, Inc.（納斯達克股票代碼：RYTM）348.9%，增持了 26,214 股。這使其持股總數達到 33,727 股，價值約為$385,000。其他機構投資者，包括 Perceptive Advisors LLC、安大略醫療養老金計劃信託基金和加拿大養老金計劃投資委員會，也大幅增加了對 Rhythm Pharmaceuticals 的持股。該公司的股票表現、季度收益和內部交易受到關注，顯示出分析師建議關注生物技術行業未來發展的混合前景</p>

<p>SG Americas Securities LLC increased its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 348.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,727 shares of the company's stock after purchasing an additional 26,214 shares during the period. SG Americas Securities LLC owned 0.06% of Rhythm Pharmaceuticals worth $1,385,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>SG Americas Securities LLC 在第二季度根據最新提交給證券交易委員會（SEC）的 13F 申報文件，將其在 Rhythm Pharmaceuticals, Inc.（NASDAQ: RYTM - 免費報告）的持股增加了 348.9%。該基金在該期間購買了額外的 26,214 股，持有公司股票 33,727 股。根據最新的 SEC 申報，SG Americas Securities LLC 持有的 Rhythm Pharmaceuticals 股份價值 1,385,000 美元，佔公司價值的 0.06%。</p>
</div><p>Get <strong>Rhythm Pharmaceuticals</strong> alerts:</p>
<ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>Rhythm Pharmaceuticals</strong> 警報：</p>
<ul>
<li>7 支將推動減肥藥市場的股票</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Perceptive Advisors LLC lifted its position in shares of Rhythm Pharmaceuticals by 465.6% in the fourth quarter. Perceptive Advisors LLC now owns 2,154,110 shares of the company's stock valued at $99,024,000 after acquiring an additional 1,773,282 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Rhythm Pharmaceuticals by 381.2% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 730,643 shares of the company's stock valued at $31,659,000 after purchasing an additional 578,800 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Rhythm Pharmaceuticals by 116.1% during the 1st quarter. Canada Pension Plan Investment Board now owns 577,000 shares of the company's stock worth $25,001,000 after purchasing an additional 310,000 shares during the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of Rhythm Pharmaceuticals during the fourth quarter worth about $12,477,000. Finally, Vanguard Group Inc. raised its position in shares of Rhythm Pharmaceuticals by 7.0% in the fourth quarter. Vanguard Group Inc. now owns 3,226,938 shares of the company's stock valued at $148,342,000 after buying an additional 212,370 shares during the last quarter.</p>
<div class="lb-trans"><p>許多其他機構投資者和對沖基金最近也買入和賣出了該股。Perceptive Advisors LLC 在第四季度將其在 Rhythm Pharmaceuticals 的持倉增加了 465.6%。Perceptive Advisors LLC 現在擁有公司股票 2,154,110 股，價值 99,024,000 美元，比上一季度增加了 1,773,282 股。安大略醫療養老金信託基金在第一季度將其在 Rhythm Pharmaceuticals 的持股增加了 381.2%。安大略醫療養老金信託基金現在擁有公司股票 730,643 股，價值 31,659,000 美元，比上一季度增加了 578,800 股。加拿大養老金計劃投資委員會在第一季度將其在 Rhythm Pharmaceuticals 的持股增加了 116.1%。加拿大養老金計劃投資委員會現在擁有公司股票 577,000 股，價值 25,001,000 美元，比上一季度增加了 310,000 股。Artisan Partners Limited Partnership 在第四季度購入了 Rhythm Pharmaceuticals 的新股份，價值約 12,477,000 美元。最後，Vanguard Group Inc.在第四季度將其在 Rhythm Pharmaceuticals 的持股增加了 7.0%。Vanguard Group Inc.現在擁有公司股票 3,226,938 股，價值 148,342,000 美元，比上一季度增加了 212,370 股。</p>
</div><h2>Rhythm Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 股價表現</h2>
</div><p>NASDAQ RYTM opened at $46.70 on Friday. The business's 50-day simple moving average is $44.81 and its 200-day simple moving average is $42.84. The firm has a market capitalization of $2.85 billion, a P/E ratio of -10.09 and a beta of 2.04. Rhythm Pharmaceuticals, Inc. has a 1-year low of $20.97 and a 1-year high of $53.92.</p>
<ul>
<li>2 biotechs with promising weight-loss drugs coming</li>
</ul>
<div class="lb-trans"><p>NASDAQ RYTM 週五開盤價為 46.70 美元。公司的 50 天簡單移動平均線為 44.81 美元，200 天簡單移動平均線為 42.84 美元。該公司的市值為 28.5 億美元，市盈率為-10.09，貝塔係數為 2.04。Rhythm Pharmaceuticals, Inc.的一年最低價為 20.97 美元，最高價為 53.92 美元。</p>
<ul>
<li>2 家有前景的減肥藥生物技術公司</li>
</ul>
</div><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.16. Rhythm Pharmaceuticals had a negative net margin of 254.88% and a negative return on equity of 221.65%. The company had revenue of $29.08 million during the quarter, compared to the consensus estimate of $28.79 million. During the same period in the previous year, the firm earned ($0.82) earnings per share. Rhythm Pharmaceuticals's revenue for the quarter was up 51.3% on a year-over-year basis. On average, equities research analysts expect that Rhythm Pharmaceuticals, Inc. will post -4.4 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（NASDAQ: RYTM - 獲取免費報告）於 8 月 6 日星期二發佈了季度財報。公司報告該季度每股虧損（EPS）為（0.55）美元，超過了每股（EPS）為（0.71）美元的共識預期 0.16 美元。Rhythm Pharmaceuticals 的淨利潤率為-254.88%，淨資產收益率為-221.65%。該季度公司營收為 2908 萬美元，高於共識預期的 2879 萬美元。與去年同期相比，Rhythm Pharmaceuticals 的季度營收增長了 51.3%。平均而言，股票研究分析師預計 Rhythm Pharmaceuticals, Inc.在本財年將實現-4.4 美元的每股收益。</p>
</div><h2>Insider Activity at Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 內部交易活動</h2>
</div><p>In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 10,468 shares of the business's stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $53.00, for a total transaction of $554,804.00. Following the transaction, the insider now owns 30 shares in the company, valued at $1,590. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Joseph Shulman sold 10,468 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $53.00, for a total transaction of $554,804.00. Following the sale, the insider now owns 30 shares in the company, valued at $1,590. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, insider Pamela J. Cramer sold 1,395 shares of the company's stock in a transaction on Monday, July 29th. The shares were sold at an average price of $49.06, for a total transaction of $68,438.70. Following the completion of the transaction, the insider now owns 31,735 shares of the company's stock, valued at $1,556,919.10. The disclosure for this sale can be found here. In the last three months, insiders sold 66,182 shares of company stock worth $3,101,567. Corporate insiders own 5.60% of the company's stock.</p>
<div class="lb-trans"><p>根據其他 Rhythm Pharmaceuticals 的消息，內部人員 Joseph Shulman 於 7 月 16 日星期二出售了 10,468 股公司股票。這些股票的平均價格為 53.00 美元，總交易額為 554,804.00 美元。交易完成後，該內部人員在公司持有 30 股，價值 1,590 美元。該交易已在 SEC 的法律文件中披露，可在 SEC 網站上找到。此外，內部人員 Joseph Shulman 於 7 月 16 日星期二又以每股 53.00 美元的平均價格出售了 10,468 股 Rhythm Pharmaceuticals 股票，總交易額為 554,804.00 美元。交易完成後，該內部人員在公司持有 30 股，價值 1,590 美元。該交易已在證券交易委員會的法律文件中披露，可在 SEC 網站上找到。此外，內部人員 Pamela J. Cramer 於 7 月 29 日星期一以每股 49.06 美元的平均價格出售了公司股票 1,395 股，總交易額為 68,438.70 美元。交易完成後，該內部人員在公司持有 31,735 股公司股票，價值 1,556,919.10 美元。過去三個月，內部人員共出售了價值 3,101,567 美元的 66182 股公司股票。公司內部人員持有公司股票的比例為 5.60%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的觀點</h2>
</div><p>Several analysts have commented on the stock. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $55.00 target price on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 7th. Wells Fargo &amp; Company dropped their target price on Rhythm Pharmaceuticals from $53.00 to $52.00 and set an &#34;overweight&#34; rating for the company in a research note on Thursday, April 18th. Bank of America lowered Rhythm Pharmaceuticals from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and decreased their price target for the stock from $49.00 to $42.00 in a research note on Wednesday, May 8th. Finally, Canaccord Genuity Group dropped their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $79.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, May 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $55.83.</p>
<div class="lb-trans"><p>一些分析師對該股發表了評論。Needham &amp; Company LLC 在 8 月 7 日星期三的研究報告中重申了對 Rhythm Pharmaceuticals 股票的 “買入” 評級，並給出了 55.00 美元的目標價。富國銀行在 4 月 18 日星期四的研究報告中將 Rhythm Pharmaceuticals 的目標價從 53.00 美元降至 52.00 美元，並給予該公司 “超重” 評級。美國銀行將 Rhythm Pharmaceuticals 的評級從 “買入” 調降至 “中性”，並將股票的價格目標從 49.00 美元降至 42.00 美元。最後，Canaccord Genuity Group 將 Rhythm Pharmaceuticals 的目標股價從 80.00 美元降至 79.00 美元，並給予該公司 “買入” 評級。一位研究分析師對該股給予持有評級，五位分析師給予買入評級。根據 MarketBeat.com 的數據，該股目前的平均評級為 “中等買入”，共識目標股價為 55.83 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on RYTM</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 RYTM 的最新研究報告</strong></p>
</div><h2>Rhythm Pharmaceuticals Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 公司簡介（免費報告）</h2>
</div><p>Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals, Inc.是一家專注於罕見神經內分泌疾病的商業階段生物製藥公司。該公司的主力產品候選藥是 IMCIVREE（setmelanotide），用於治療 POMC、PCSK1、LEPR 缺陷性肥胖以及 Bardet-Biedl 綜合徵和 Alström 綜合徵。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Rhythm Pharmaceuticals</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Michael Burry's Alibaba Bet and the Broader Market Implications</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Jeff Brown's Exegesis AI Stock Picks</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>五隻我們比 Rhythm Pharmaceuticals 更喜歡的股票</li>
<li>什麼是債券市場假日？如何投資和交易</li>
<li>邁克爾·伯裏的阿里巴巴賭注及更廣泛的市場影響</li>
<li>如何投資 FAANG 股票</li>
<li>傑夫·布朗的 Exegesis AI 股票推薦</li>
<li>對投資者最重要的沃倫·巴菲特股票：他自己的</li>
<li>沃倫·巴菲特的賭注：為什麼伯克希爾·哈撒韋購買了奧爾特股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RYTM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ The 2024 Tech Panic: What Billionaires Know That You Don’t (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 2024 年的科技恐慌：億萬富翁知道的你不知道的（來自 InvestorPlace）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9179&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Rhythm Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元購買 Rhythm Pharmaceuticals？</h2>
</div><p>Before you consider Rhythm Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rhythm Pharmaceuticals 之前，您需要聽到這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單...而 Rhythm Pharmaceuticals 並不在其中。</p>
</div><p>While Rhythm Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Rhythm Pharmaceuticals 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

SG Americas Securities LLC 增持 Rhythm Pharma, Inc. (納斯達克:RYTM) 的股份